Use of NovoSeven® in Active Variceal Bleeding

Novo Nordisk A/S265 enrolled

Overview

This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

265

Conditions

Acquired Bleeding Disorder Cirrhosis

Interventions

activated recombinant human factor VIIDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Variceal bleeding

Locations (44)

Outcomes

Primary Outcomes

Treatment failure

Time frame: Within 5 days after first trial product administration

Secondary Outcomes

Mortality

Rebleeding

Control of acute bleeding

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.